Table of Contents Author Guidelines Submit a Manuscript
Evidence-Based Complementary and Alternative Medicine
Volume 2015, Article ID 767136, 14 pages
http://dx.doi.org/10.1155/2015/767136
Review Article

Overcome Cancer Cell Drug Resistance Using Natural Products

School of Life Sciences, Shanxi University, Taiyuan, Shanxi 030006, China

Received 17 May 2015; Revised 12 July 2015; Accepted 30 July 2015

Academic Editor: Yew-Min Tzeng

Copyright © 2015 Pu Wang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. B. Stewart and C. P. Wild, World Cancer Report, IARC Nonserial Publication, 2014.
  2. J. L. Markman, A. Rekechenetskiy, E. Holler, and J. Y. Ljubimova, “Nanomedicine therapeutic approaches to overcome cancer drug resistance,” Advanced Drug Delivery Reviews, vol. 65, no. 13-14, pp. 1866–1879, 2013. View at Publisher · View at Google Scholar · View at Scopus
  3. D. C. Swinney and J. Anthony, “How were new medicines discovered?” Nature Reviews Drug Discovery, vol. 10, no. 7, pp. 507–519, 2011. View at Publisher · View at Google Scholar · View at Scopus
  4. C. Basmadjian, Q. Zhao, E. Bentouhami et al., “Cancer wars: natural products strike back,” Frontiers in Chemistry, vol. 2, article 20, 2014. View at Publisher · View at Google Scholar
  5. P. A. Sotiropoulou, M. S. Christodoulou, A. Silvani, C. Herold-Mende, and D. Passarella, “Chemical approaches to targeting drug resistance in cancer stem cells,” Drug Discovery Today, vol. 19, no. 10, pp. 1547–1562, 2014. View at Publisher · View at Google Scholar · View at Scopus
  6. A. Cort and T. Ozben, “Natural product modulators to overcome multidrug resistance in cancer,” Nutrition and Cancer, vol. 67, no. 3, pp. 411–423, 2015. View at Publisher · View at Google Scholar · View at Scopus
  7. D.-M. Zhang, C. Shu, J.-J. Chen et al., “BBA, a derivative of 23-hydroxybetulinic acid, potently reverses ABCB1-mediated drug resistance in vitro and in vivo,” Molecular Pharmaceutics, vol. 9, no. 11, pp. 3147–3159, 2012. View at Publisher · View at Google Scholar · View at Scopus
  8. H.-Q. Guo, G.-N. Zhang, Y.-J. Wang et al., “β-Elemene, a compound derived from Rhizoma zedoariae, reverses multidrug resistance mediated by the ABCB1 transporter,” Oncology Reports, vol. 31, no. 2, pp. 858–866, 2014. View at Publisher · View at Google Scholar · View at Scopus
  9. X.-C. Huang, X. Xiao, Y.-K. Zhang et al., “Lamellarin O, a pyrrole alkaloid from an Australian marine sponge, Ianthella sp., reverses BCRP mediated drug resistance in cancer cells,” Marine Drugs, vol. 12, no. 7, pp. 3818–3837, 2014. View at Publisher · View at Google Scholar · View at Scopus
  10. Y. Zhang, Y. Zhang, Y. Wang et al., “Esters of the marine-derived triterpene sipholenol A reverse P-GP-mediated drug resistance,” Marine Drugs, vol. 13, no. 4, pp. 2267–2286, 2015. View at Publisher · View at Google Scholar
  11. G. Housman, S. Byler, S. Heerboth et al., “Drug resistance in cancer: an overview,” Cancers (Basel), vol. 6, no. 3, pp. 1769–2792, 2014. View at Publisher · View at Google Scholar
  12. Q. Wu, Z. Yang, Y. Nie, Y. Shi, and D. Fan, “Multi-drug resistance in cancer chemotherapeutics: mechanisms and lab approaches,” Cancer Letters, vol. 347, no. 2, pp. 159–166, 2014. View at Publisher · View at Google Scholar · View at Scopus
  13. R. K. Vadlapatla, A. D. Vadlapudi, D. Pal, and A. K. Mitra, “Mechanisms of drug resistance in cancer chemotherapy: coordinated role and regulation of efflux transporters and metabolizing enzymes,” Current Pharmaceutical Design, vol. 19, no. 40, pp. 7126–7140, 2013. View at Publisher · View at Google Scholar · View at Scopus
  14. F. J. Sharom, “ABC multidrug transporters: structure, function and role in chemoresistance,” Pharmacogenomics, vol. 9, no. 1, pp. 105–127, 2008. View at Publisher · View at Google Scholar · View at Scopus
  15. L. A. Doyle, W. Yang, L. V. Abruzzo et al., “A multidrug resistance transporter from human MCF-7 breast cancer cells,” Proceedings of the National Academy of Sciences of the United States of America, vol. 95, no. 26, pp. 15665–15670, 1998. View at Publisher · View at Google Scholar · View at Scopus
  16. P. A. Fetsch, A. Abati, T. Litman et al., “Localization of the ABCG2 mitoxantrone resistance-associated protein in normal tissues,” Cancer Letters, vol. 235, no. 1, pp. 84–92, 2006. View at Publisher · View at Google Scholar · View at Scopus
  17. E. L. Niero, B. Rocha-Sales, C. Lauand et al., “The multiple facets of drug resistance: one history, different approaches,” Journal of Experimental & Clinical Cancer Research, vol. 33, no. 1, article 37, 2014. View at Publisher · View at Google Scholar · View at Scopus
  18. I. R. Indran, G. Tufo, S. Pervaiz, and C. Brenner, “Recent advances in apoptosis, mitochondria and drug resistance in cancer cells,” Biochimica et Biophysica Acta—Bioenergetics, vol. 1807, no. 6, pp. 735–745, 2011. View at Publisher · View at Google Scholar · View at Scopus
  19. D. S. Backos, C. C. Franklin, and P. Reigan, “The role of glutathione in brain tumor drug resistance,” Biochemical Pharmacology, vol. 83, no. 8, pp. 1005–1012, 2012. View at Publisher · View at Google Scholar · View at Scopus
  20. F. Joncourt, K. Buser, H. Altermatt, M. Bacchi, A. Oberli, and T. Cerny, “Multiple drug resistance parameter expression in ovarian cancer,” Gynecologic Oncology, vol. 70, no. 2, pp. 176–182, 1998. View at Publisher · View at Google Scholar · View at Scopus
  21. J. A. Green, L. J. Robertson, and A. H. Clark, “Glutathione S-transferase expression in benign and malignant ovarian tumours,” British Journal of Cancer, vol. 68, no. 2, pp. 235–239, 1993. View at Publisher · View at Google Scholar · View at Scopus
  22. B. V. Jardim, M. G. Moschetta, C. Leonel et al., “Glutathione and glutathione peroxidase expression in breast cancer: an immunohistochemical and molecular study,” Oncology Reports, vol. 30, no. 3, pp. 1119–1128, 2013. View at Publisher · View at Google Scholar · View at Scopus
  23. P. Yu, Y. Du, X. Cheng, Q. Yu, L. Huang, and R. Dong, “Expression of multidrug resistance-associated proteins and their relation to postoperative individualized chemotherapy in gastric cancer,” World Journal of Surgical Oncology, vol. 12, article 307, 2014. View at Publisher · View at Google Scholar · View at Scopus
  24. J. Ge, A.-X. Tian, Q.-S. Wang et al., “The GSTP1 105Val allele increases breast cancer risk and aggressiveness but enhances response to cyclophosphamide chemotherapy in North China,” PLoS ONE, vol. 8, no. 6, Article ID e67589, 2013. View at Publisher · View at Google Scholar
  25. E. J. Kap, S. Richter, A. Rudolph et al., “Genetic variants in the glutathione S-transferase genes and survival in colorectal cancer patients after chemotherapy and differences according to treatment with oxaliplatin,” Pharmacogenetics and Genomics, vol. 24, no. 7, pp. 340–347, 2014. View at Publisher · View at Google Scholar · View at Scopus
  26. X. H. Wang, S. J. Zhang, X. Guo, M. L. Sun, Q. P. Li, and H. Y. Liu, “Reversal effect and mechanism of osthole on the multidrug-resistance of human bladder cancer cells T24/ADM,” China Modern Medicine, vol. 19, pp. 7–9, 2012. View at Google Scholar
  27. L. Nong, G. Wu, X. F. Dai et al., “Mechanism of reversing MDR of human lung adenocarcinoma cell line A549/DDP by evodiamine,” Chinese Clinical Oncology, vol. 15, pp. 487–492, 2010. View at Google Scholar
  28. J. Hu, Y. Zhang, B. G. Ma, Y. P. Ju, Y. L. Li, and W. Cheng, “The experimental studies of celastrol on the reversal of multidrug resistance in K562/A02 cell line,” The Practical Journal of Cancer, vol. 26, pp. 226–229, 2011. View at Google Scholar
  29. R. Hu, K. Zhu, X. Y. Zhang et al., “Embelin overcome the resistance of K562/D to daunorubicin,” Journal China Medical Univrsity, vol. 39, pp. 272–275, 2010. View at Google Scholar
  30. H. W. Yang, C. X. Qu, H. W. Guan, and H. W. Yang, “Arsenic trioxide reversing the multidrug resistance of gastric carcinoma cell line SGC7901/ADR to adriamycin,” Cancer Research on Prevention and Treatment, vol. 33, pp. 148–149, 2006. View at Google Scholar
  31. M. Liang, Y. Q. Zhou, S. J. Xiao, and Z. K. Dai, “Netferine reverses drug resistance of human ovarian cancer SKOV3/DDP cells,” Shandong Medical Journal, vol. 51, pp. 39–41, 2011. View at Google Scholar
  32. W. G. Wang, G. Q. Yu, G. Y. Zhang, C. Zhang, and H. Dong, “Quercetin overcomes drug resistance of K562/ADM cells,” Heilongjiang Medicine and Pharmacy, vol. 34, pp. 28–29, 2011. View at Google Scholar
  33. Y.-Y. Chen, J. Li, J.-D. Hu et al., “Reversing effects of emodin on multidrug resistance in resistant HL-60/ADR cells,” Journal of Experimental Hematology, vol. 21, no. 6, pp. 1413–1422, 2013. View at Google Scholar · View at Scopus
  34. L. Liang, S. Y. Liu, J. Wang, and W. Jiang, “Irisquinone overcomes drug resistance of A549/DDP cells,” National Medical Journal of China, vol. 81, pp. 1392–1393, 2001. View at Google Scholar
  35. M. H. Liu, M. P. Ren, R. Li, Z. Zhang, and S. H. Xiao, “Reversal effect of tetramethylpyrazine on cisplatin-resistant ovarian cancer cell line COC1/DDP,” Chongqing Medicine, vol. 40, pp. 1982–1987, 2011. View at Google Scholar
  36. H.-G. Qu, L. Gao, D. He et al., “Effect of reversion of ganoderma lucidum polysaccharides on cisplatin resistant in ovarian cancer cells and its mechanism,” Journal of Jilin University Medicine Edition, vol. 37, no. 2, pp. 250–254, 2011. View at Google Scholar · View at Scopus
  37. L. G. Lu, M. D. Zeng, Y. M. Mao et al., “Oxymatrine in the treatment of chronic hepatitis B for one year: a multicenter random double-blind placebo-controlled trial,” Zhonghua Gan Zang Bing Za Zhi, vol. 12, no. 10, pp. 597–600, 2004. View at Google Scholar
  38. B.-S. Shen and X.-W. Song, “Effects of oxymatrine on serum cytokines and hepatic fibrotic indexes in patients with chronic hepatitis B,” Zhongguo Zhong Xi Yi Jie He Za Zhi, vol. 28, no. 1, pp. 17–19, 2008. View at Google Scholar · View at Scopus
  39. K. Liang, W. Wei, and Y. Y. Guan, “Clinical application prospects of berberine,” Medical Recapitulate, vol. 18, pp. 2842–2843, 2012. View at Google Scholar
  40. M. L. Duan and J. Song, “Pharmacology of ephedrine,” in Proceedings of the Symposium of Chinese Annual Meeting of Anesthesia, 2008.
  41. C. Fan, “The observation of the effects of disodium norcantharidate in the treatment of advanced primary liver cancer,” Journal of Basic and Clinical Oncology, vol. 23, pp. 50–51, 2010. View at Google Scholar
  42. Y. L. Wang, X. L. Bi, J. Gu, and S. Q. Gao, “Study on the mechanism of baicalin in psoriasis treatment,” Chinese Journal of Dermatovenerology of Integrated Traditional and Western Medicine, vol. 2, pp. 209–211, 2003. View at Google Scholar
  43. I. Hiroko, A. Sakae, and O. Yukio, “Effect of shosaikoto, a japanese and chinese traditional herbal medicinal mixture, on the mitogenic activity of lipopolysaccharide: a new pharmacological testing method,” Journal of Ethnopharmacology, vol. 21, no. 1, pp. 45–53, 1987. View at Publisher · View at Google Scholar · View at Scopus
  44. W. L. Deng, J. H. Xu, C. L. Li, Y. Sun, Y. Zhang, and Z. Z. Fan, “Reversal of multidrug resistance by Changweiqing on vincristine-resistant human colorectal cancer cell line HCT8/V,” Tumor, vol. 28, pp. 755–757, 2008. View at Google Scholar
  45. J. H. Xu, Z. Z. Fan, J. Sun et al., “Reversal of mulitdrug resistance by Changweiqing oral liquid on human oral epidermoid carcinoma cell line KB-A-1,” Tumor, vol. 25, pp. 562–565, 2005. View at Google Scholar
  46. X. M. Ji, B. Ouyang, C. Y. Wang, Y. Q. Zhang, and T. Jiang, “Wenxiafang, a traditional Chinese college of basic medical sciences, chemotherapeutic resistance in A549/DDP cells by down-regulating expression levels of P-gp, LRP and MRP,” China Remedies & Clinics, vol. 6, pp. 885–888, 2006. View at Google Scholar
  47. J. Liu, “Treatment of constipation using Changweiqing,” Shanxi Journal of Traditional Chinese Medicine, vol. 29, pp. 11–12, 2013. View at Google Scholar
  48. Q. Cao, Y. Sun, J. F. Shen, and Z. Z. Fan, “Clinical use of Changweiqing to control the infection of Helicobacter pylori,” Chinese Journal of Digestion, vol. 20, p. 21, 2000. View at Google Scholar
  49. Y. X. He, “Clinical treatment of chronic gastritis using changweiqing,” Health Must-Read, vol. 12, p. 248, 2013. View at Google Scholar
  50. Y. Zhang, H. Lu, X. W. Sun, Z. Z. Fan, J. Sun, and J. H. Xu, “Effects of Changweiqing in reversing oxaliplatin resistant HCT116/L-OHP and influence on Pt-DNA adduct,” Chinese Traditional Patent Medicine, vol. 34, pp. 1843–1848, 2012. View at Google Scholar
  51. F. B. Feng, J. Zhuang, H. E. Han, Q. L. Lv, and C. G. Sun, “Research on Chinese herbal compound of reducing phlegm and resolving masses on reversal of multidrug resistance mechanism of MCF-7/ADM transplantation tumor in nude mice,” Acta Academiae Medicinae Weifang, vol. 36, pp. 211–213, 2014. View at Google Scholar
  52. G. Liang, X. Z. Lin, L. Li, M. Zhou, and A. Z. Tang, “MDR-reversing effect of (-)epigallocatechin-3-gallate on human MDR cell lines KBV200,” Cancer Research on Prevention and Treatment, vol. 34, pp. 4–7, 2007. View at Google Scholar
  53. L. Wang, P. K. Wei, Z. F. Qin et al., “Experimental study on puerarin injection reverse multidrug resistance of nude mice of human gastric carcinoma constructed using orthotopic transplantation,” Journal of Chengdu University of Traditional Chinese Medicine, vol. 28, pp. 42–46, 2005. View at Google Scholar
  54. W. D. Lu, Z. X. Fu, Y. Qin, L. Li, and C. Yang, “Curcumin reverses multidrug resistance in HCT-8/VCR nude mice xenograft,” Acta Academiae Medicinae Militaris Tertiae, vol. 33, pp. 376–380, 2011. View at Google Scholar
  55. X. Wang, Establishment of Hca multidrug resistance mouse model and study of cepharanthine hydrochloride on overcoming its drug resistance [M.S. thesis], Zhenzhou University, 2008.
  56. F. Sun, N. Wang, G. Li, X. Wang, X. Li, and G. Yin, “The effect of matrine on the expression of P170 LRP and TOPO II of obtained multi-drug resistance of mouse S180's tumour cell,” Journal of Chinese Medicinal Materials, vol. 27, no. 11, pp. 838–840, 2004. View at Google Scholar · View at Scopus
  57. F.-J. Sun, X.-C. Nie, G.-H. Li, and G.-P. Yin, “The study of tetrandrine on reversion of P170 and apoptosis of obtained multi-drug resistante of mice S180's tumour cell,” China Journal of Chinese Materia Medica, vol. 30, no. 4, pp. 280–283, 2005. View at Google Scholar · View at Scopus
  58. K. W. Hu, X. Y. Chen, M. H. Zuo et al., “Fritillaria thunbergii powder overcomes drug resistance of acute leukemia patients,” China Journal of Traditional Chinese Medicine and Pharmacy, vol. 19, pp. 68–70, 2004. View at Google Scholar
  59. W. Li, K. W. Hu, W. Su, Y. L. Sun, X. Y. Chen, and B. Liang, “Clinical trial of Fritillaria thunbergii Bulb powder for reversing multidrug resistance in the patients with acute leukemia,” Journal of Beijing University of Traditional Chinese Medicine, vol. 27, pp. 63–65, 2004. View at Google Scholar
  60. Y. C. Zhao, X. Y. Chen, Y. M. Xu, and Z. Jia, “Principal clinical study on ligustrazine injection to counteract the multi-drug resistance of acute leukemia,” Chinese Journal of Information on Traditional Chinese Medicine, vol. 10, pp. 10–11, 2003. View at Google Scholar
  61. L. Q. Zhu, S. Xu, L. Luo, Z. Li, L. L. Qiu, and C. F. Xu, “Reversal of multidrug resistance in drug-resistance human choriocarcinoma cell line JAR/VP16 by effective component of Verbena officinalis L.,” Acta Universitatis Medicinalis Nanjing, vol. 27, pp. 419–423, 2007. View at Google Scholar
  62. J. H. Li, G. Q. Qin, and P. M. Yang, “Reversal of multidrug resistance in human K562/ADM cell line by dauricine,” Journal of Dalian Medical University, vol. 24, pp. 94–96, 2002. View at Google Scholar
  63. W. Q. Chen, H. W. Qi, C. G. Wu, Z. K. Li, C. W. Bai, and Y. G. Liu, “Inhibition of growth on the human lung adenocarcinoma cell line A549 and A549/CDDP in vitro by dihydroartemisinin in combination with cisplatin,” Journal of Modern Oncology, vol. 14, pp. 284–286, 2006. View at Google Scholar
  64. H. Zhang, H.-Q. Wang, H.-L. Zhang, D. Kong, and X.-Z. Wu, “Ginsenoside Rh2 reverses p-glycoprotein-mediated multidrug resistance of MCF-7/ADM cells,” Tumor, vol. 27, no. 5, pp. 365–369, 2007. View at Google Scholar · View at Scopus
  65. Y. L. Zhou, Z. W. Zhou, and R. Zeng, “Reversal effect of isorhynchophylline on cisplatin resistance of line A549/DDP human lung adenocarcinoma cells,” Central South Pharmacy, vol. 6, pp. 267–269, 2008. View at Google Scholar
  66. Y. L. Zhou, M. X. Tang, and S. K. Liu, “Reversal effect of isorhynchophylline on lung adenocarcinoma drug-resistant cell line A549/DDP,” Chinese Journal of New Drugs, vol. 18, p. 1338, 2009. View at Google Scholar
  67. Z. W. Zhou and Y. L. Zhou, “Effect of isorhynchophylline liposomes on cisplatin resistance of human lung adenocarcinoma cell line A549/DDP,” Journal of Traditional Chinese Medicine University of Hunan, vol. 28, pp. 29–31, 2008. View at Google Scholar
  68. J. H. Li and P. M. Yang, “Study on ligustrazine in reversing multidrug resistance of K562/ADM cell,” Modern Journal of Integrated Traditional Chinese and Western Medicine, vol. 10, pp. 1405–1407, 2001. View at Google Scholar
  69. Q. Fan, G. J. Fan, J. Y. Zhao, and P. M. Yang, “Study on effect reversing MDR of ligustrazine liposomes on human erythroleukemia-cell-line K562/ADM,” China Pharmacist, vol. 7, pp. 753–755, 2004. View at Google Scholar
  70. Y. F. Ding, X. Xie, J. Y. Zhao, and P. M. Yang, “Reversal of adriamycin resistance by matrine in leukemia multidrug resistance cell line K562/ADM,” Journal of Dalian Medical University, vol. 26, pp. 256–259, 2004. View at Google Scholar
  71. P. Zhang, Z. Y. Gu, Y. H. Sun, and Y. Z. Nie, “Reversal effect of peiminine on gastric cancer multidrug resistance,” Journal of Xinjiang Medical University, vol. 35, pp. 452–456, 2012. View at Google Scholar
  72. L. Li and Q. X. Fan, “Reversal effect of schisandrin A on MRP1-mediated multidrug resistance,” Journal of Chinese Practical Diagnosis and Therapy, vol. 23, pp. 857–859, 2009. View at Google Scholar
  73. D. Pang, Study of the reversal effect of tanshinone II. A on multidrug-resistance of breast cancer [M.S. thesis], Sichuan University, 2007.
  74. Y. Q. Shi, M. Deng, L. X. Zhu, and R. X. Yu, “Primary study on reversal effect of radix acanthoparacis senticosi on multidrug resistance of K562/ADR cells in vitro,” Chinese Journal of Traditional Medical Science and Technology, vol. 11, pp. 93–95, 2004. View at Google Scholar
  75. Y. Han, L. M. Bu, X. Ji, C. Y. Liu, and Z. H. Wang, “Modulation of multidrug resistance by andrographolid in a HCT-8/5-FU multidrug-resistant colorectal cancer cell line,” Chinese Journal of Digestive Diseases, vol. 6, no. 2, pp. 82–86, 2005. View at Publisher · View at Google Scholar · View at Scopus
  76. B. Jiang and Q. L. Liu, “The reverse role of the activity of Banlangen to human multidrug-resistant hepatocarxinoma cell,” Journal of Jining Medical College, vol. 27, pp. 11–13, 2004. View at Google Scholar
  77. H. Liu, “Reversal effect of Angelicae sinensis on DOX resistance gastric cancer cell line SGC-7901/ADR,” World Health Digest, vol. 6, pp. 31–33, 2009. View at Google Scholar
  78. B. Liao, R. Y. Ge, C. B. Xu et al., “Reversal effect of Chinese medicine compound FFJZ on multidrug resistance of leukemia K562/VCR cell line,” Journal of Fujian University of Traditional Chinese Medicine, vol. 21, pp. 9–12, 2011. View at Google Scholar
  79. H. J. Xing, H. Y. Cui, and J. H. Zhao, “Apigenin reverses drug resistance of HCT8/5-FU cells by down-regulation of MDR1,” Chinese Journal Gerontology, vol. 34, pp. 3709–3712, 2014. View at Google Scholar
  80. J. Cheng, J. P. Feng, Y. P. Wang, M. Li, and Q. Z. Kong, “Effect of arsenic trioxide on MRP expression in A549/R cell line of human lung cancer,” Herald of Medicine, vol. 26, pp. 457–460, 2007. View at Google Scholar
  81. H. Li, M.-M. Xiong, X.-L. Meng, and X.-P. Geng, “Reversing effect of arsenic trioxide on multidrug resistance of human hepatocellular carcinoma HepG2/ADM cells,” World Chinese Journal of Digestology, vol. 14, no. 27, pp. 2691–2694, 2006. View at Google Scholar · View at Scopus
  82. H. W. Yang, C. X. Qu, and H. W. Guan, “Arsenic trioxide reversing the multidrug resistance of gastric carcinoma cell line SGC7901/ADR to adriamycin,” Cancer Research on Prevention and Treatment, vol. 33, pp. 148–149, 2006. View at Google Scholar
  83. H. P. Yu, L. Cui, and Y. J. Pan, “Reversal of drug resistance in multidrug-resistant MCF-7/ADR cells of breast cancer by artemisinin,” Acta Medicinae Universitatis Scientiae et Technologiae Huazhong, vol. 40, pp. 91–94, 2011. View at Google Scholar
  84. X. J. Fu, H. Yao, L. E. Lin et al., “Study on artesunate in reversing MDR of multiple myeloma cell lines,” Acta Universitatis Medicinalis Anhui, vol. 48, pp. 1075–1078, 2013. View at Google Scholar
  85. L. J. Yang, T. Zhao, Q. X. Bai, and H. J. Dong, “Reversal effect and machenism induced by baicalin on leukemia cell line,” Shanxi Medical Journal, vol. 41, pp. 775–779, 2012. View at Google Scholar
  86. S. H. Wang, “The multidrug-resistant mechanism study of reverse effect of Baicalin for hepatocellular carcinoma cell line (Bel 7402/ADM),” Chinese Journal of Modern Drug Application, vol. 6, pp. 10–11, 2012. View at Google Scholar
  87. Y. Q. Han, Y. J. Shi, J. Y. Yuan, Y. Zhu, and S. L. Wu, “The study of reversal resistance effect and its mechanism of berbamine in MCF7/ADR cells,” Acta Anatomica Sinica, vol. 35, pp. 161–164, 2004. View at Google Scholar
  88. Y. Wu, Y. Zeng, and S. Y. Liang, “The exploratory research on the berberine reverse the HCT-8/VCR multidrug resistance and its relationship with P-gp functional variance,” Guide of China Medicine, vol. 8, pp. 18–20, 2010. View at Google Scholar
  89. X. L. Yu, H. Li, X. L. Chen, X. X. Li, R. Wang, and F. Gao, “Study on reversing mechanism of multidrug resistance of K562/A02 cell line by carnosic acid,” Chinese Journal of Hematology, vol. 31, pp. 381–384, 2010. View at Google Scholar
  90. Z. Cao, L.-J. Wang, M.-H. Wu, Y. Qiao, Y.-J. Sun, and J. Guo, “Mechanism governing reversal of multidrug resistance in human breast carcinoma cells by chelerythrine,” Acta Academiae Medicinae Sinicae, vol. 33, no. 1, pp. 45–50, 2011. View at Publisher · View at Google Scholar · View at Scopus
  91. Y. Qin, Z. X. Fu, W. D. Lu, L. Li, and W. X. Tang, “Experimental study of multidrug-resistance reversing of curcumin on human colon carcinoma HCT-8/VCR cells,” Chinese Journal of Biochemical Pharmaceutics, vol. 32, pp. 173–179, 2011. View at Google Scholar
  92. H. Y. Chang, F. C. Oan, X. Y. Jiao et al., “The study on reversing mechanism of multidrug resistance of K562/A02 cell line by curcumin and erythromycin,” Chinese Journal of Hematology, vol. 27, pp. 254–257, 2006. View at Google Scholar
  93. L. Wang, P. K. Wei, Z. F. Qin et al., “Experimental study on reversion effect of elemene on multidrug resistance of human gastric cancer cell line,” Journal of Chengdu University of Traditional Chinese Medicine, vol. 28, pp. 51–53, 2005. View at Google Scholar
  94. C. M. Chen, W. Z. Yang, C. H. Wang, X. Y. Yang, and S. S. Shi, “Reverse of drug resistance against ADM in U251/ADM cells by elemene,” Chinese Journal of Experimental Surgery, vol. 23, pp. 601–603, 2006. View at Google Scholar
  95. C. C. Yao, Y. R. Tu, J. Jiang et al., “Elemene reversed the multidurg resistance of A549/DDP lung cancer cells via mitochondrial apoptosis pathway,” Journal of Modern Oncology, vol. 22, pp. 1276–1281, 2014. View at Google Scholar
  96. J. Q. Mao, Y. Zhang, J. Gu, X. Zhang, and L. Ma, “Reversal of multidrug resistance in K562/A02 cell by ephedrine,” Chinese Journal of Hospital Pharmacy, vol. 27, pp. 156–159, 2007. View at Google Scholar
  97. F. Zhao, M. H. Zhang, X. L. Chen et al., “MDR-reversing effect of EGCG by decreasing expression of p-glycoprotein on human leukemic cell line,” Journal of Oncology, vol. 10, pp. 389–392, 2004. View at Google Scholar
  98. Y. H. Li, “Experimental study on EGCG reversing the multidrug resistance of esophageal cancer cell line Eca109/DDP,” Guide of Chinese Medicine, vol. 11, pp. 414–415, 2013. View at Google Scholar
  99. P. Yang, J. Cao, M. H. Tan et al., “Reversal of resistance to Oxaliplatin in human colon cancer by gambogic acid,” Chinese Archives of General Surgery (Electronic Edition), vol. 7, pp. 273–277, 2013. View at Google Scholar
  100. Y. Li, Z. Z. Wang, and T. F. Yu, “In vitro study on the reversal of multidrug resistance (MDR) in HL60/VCR cell line with ginsenoside-Rb1,” Journal of Radioimmunology, vol. 18, pp. 362–365, 2005. View at Google Scholar
  101. H. L. Wen, X. M. Li, W. T. Zeng, and K. L. Zhu, “Effect of ginsenoside on reversal of multidrug resistance of hepatocellular carcinoma cells bel-7402: an experimental study,” Chinese Journal of Biomedical Engineering, vol. 18, pp. 191–194, 2012. View at Google Scholar
  102. W. Zhang, S. Y. Liu, J. Wang et al., “Reversal effect of ginsenoside Rg3 on cisplatin-resistant human lung adenocarcinoma cell line (A549DDP) and its mechanisms,” Chinese Journal of Respiratory and Critical Care Medicine, vol. 1, pp. 100–103, 2002. View at Google Scholar
  103. L. Dong, X. Q. Tang, J. G. Cao, S. H. Shi, Y. Z. Zhuang, and J. G. Zhou, “Reversal effect of neferine on resistance to vincristine in human multidrug-resistant gastric carcinoma cell line SGC7901/VCR,” Chinese Journal of Pathophysiology, vol. 20, pp. 1407–1410, 2004. View at Google Scholar
  104. X.-B. Xiao, Z.-X. Xie, J. Chen, Q. Qin, and Y. Zhu, “Effect of neferine on the chemotherapic sensitivity of STI 571 to K562/A02 cells,” Journal of Central South University (Medical Sciences), vol. 30, no. 5, pp. 558–561, 2005. View at Google Scholar · View at Scopus
  105. C. H. Huang and P. G. Cai, “The study of neferine on multidrug resistance reversing of the human breast cancer cell line MCF-7/Adr,” Cancer Research on Prevention and Treatment, vol. 34, pp. 351–353, 2007. View at Google Scholar
  106. J. J. Guo, X. L. Pan, C. W. Feng, and J. H. Zhou, “Study on reversal effects of Oridonin on multidrug resistant cell line K562/A02,” Shanghai Medical Journal, vol. 25, pp. 43–45, 2002. View at Google Scholar
  107. J. Y. Lv and Y. Zhao, “Oxymatrine overcomes the drug resistance of MCF-7/ADM cells,” China Modern Doctor, vol. 48, pp. 86–87, 2010. View at Google Scholar
  108. X. Y. Tang and Y. X. Tang, “Efficiency and mechanisms of peimine reversing multi-drug resistance of A549/DDP cell line,” Shandong Medical Journal, vol. 52, pp. 4–6, 2012. View at Google Scholar
  109. Y. Cai, T. G. Cai, F. D. Tang, R. H. Zhang, L. He, and L. Q. Xu, “Reversal effect of multidrug resistance on K562/ADM cell by Psoralen,” Chinese Journal of Clinical Oncology, vol. 31, pp. 146–148, 2004. View at Google Scholar
  110. F. B. Du, M. H. Bao, and X. D. Mei, “Research on the reversal of multidrug resistance of human carcinoma cell line KB-MRP by quercetin,” Chinese Clinical Oncology, vol. 12, pp. 659–662, 2007. View at Google Scholar
  111. X. H. Qiao, H. F. Tang, L. Song, S. Y. Long, D. X. Zhou, and S. C. Liu, “Quercetin reverses drug resistance of leukemia cells,” Chinese Journal of Clinical Pharmacology and Therapeutics, vol. 8, pp. 302–303, 2003. View at Google Scholar
  112. S. X. Chen, Y. Y. Jiang, and Z. H. Fei, “Reversal effect of sodium norcantharidate on human lung adenocarcinoma cell line A549/DDP in vitro,” Chinese Journal of Geriatrics, vol. 29, pp. 486–488, 2010. View at Google Scholar
  113. X. L. Zhao and G. C. Xu, “A study of the reverse effect of tetramethylpyrazine on the resistant cell strain A2780/ADM of human ovarian carcinoma,” The Journal of Medical Research, vol. 38, pp. 78–81, 2009. View at Google Scholar
  114. J. L. Liu, J. Jiang, M. Y. Zhang, Y. Wang, Y. R. Liu, and Y. Wang, “Studies of TMP on restraining proliferation and reversing multidrug resistance in human lung adenocarcinoma cell line,” Practical Oncology Journal, vol. 27, pp. 303–307, 2013. View at Google Scholar
  115. H.-Y. Ma, J.-Y. Zhao, W. Jin, and L. Kong, “Effect of tetramethylpyrazine on reversing multidrug resistance of K562/MDR cells with gene transfer,” Journal of Jilin University (Medicine Edition), vol. 35, no. 4, pp. 599–603, 2009. View at Google Scholar · View at Scopus
  116. Y. Sun, K. Q. He, and M. J. Gong, “Reversal effect of tetredrine (TTD) on human hepatocellular carcinoma (HCC) multidrug-resistant cell line (Hep-3B/ADM),” China Medicine, vol. 3, pp. 790–791, 2008. View at Google Scholar
  117. L. F. Yu, Y. L. Wu, and Y. P. Zhang, “Reversal of drug resistance in the vincristine-resistant human gastric cancer cell lines MKN28/VCR by emulsion of seminal oil of Brucea javanica,” World Chinese Journal of Digestology, vol. 9, no. 4, pp. 376–378, 2001. View at Google Scholar · View at Scopus
  118. C. L. Ji, Y. Y. Xie, and D. X. Sun, “Jave Brucea fruit extract overcomes drug resistance of K562/ADM cells,” Zhejiang Journal of Traditional Chinese Medicine, vol. 45, pp. 458–459, 2010. View at Google Scholar
  119. C. Zhang, D. M. Wan, and W. J. Cao, “Reversal effect of cinobufacini on multidrug resistance of Raji/ADR cells and its mechanisms,” Journal of Experimental Hematology, vol. 22, pp. 1306–1310, 2014. View at Google Scholar
  120. G. Y. Zhou, L. Li, F. Yu, Y. L. Sun, and C. Ma, “Reversal of grape seed polyphenol on multidrug resistance of MCF 7/ADR in vitro and in vivo,” Journal of Shandong University (Health Sciences), vol. 42, pp. 640–642, 2004. View at Google Scholar
  121. F. F. Yang, Z. M. Wang, and X. L. Wu, “Study on reversal of mutidrug resistance of GBC-SD cell lines by grape seed polyphenols,” Chinese Journal of General Surgery, vol. 15, pp. 202–205, 2006. View at Google Scholar
  122. L. P. Wang, B. Z. Wang, H. Y. Si, C. Zhao, and Z. X. Sui, “Effects of hyaluronate oligomers on drug resistant reverse and apoptosis enhancement in MCF-7/ADM cell line,” Bulletin of Chinese Cancer, vol. 15, pp. 617–619, 2006. View at Google Scholar
  123. R. Li, S. Xie, L. Zhang, and X. M. Wang, “Primary study on the mechanism of reversal drug-resistance of human breast cancer cell line MCF-7 by Huaier Granule,” China Practical Medical, vol. 4, pp. 1–2, 2009. View at Google Scholar
  124. Z. Yu, T. Wu, and Y. Zhang, “The reversal effects of trametes robiniophila murr. on multidrug resistance in resistant human hepatocellular carcinoma cell line BEL-7402/5-Fu,” Journal of Chinese Oncology, vol. 19, pp. 443–447, 2013. View at Google Scholar
  125. N. Liu, X. P. Gen, L. X. Zhu et al., “MDR-reversing effect of extractum Trametes robiniophila Murr on human hepatocellular carcinoma HepG2/ADM in vitro,” Chinese Journal of Hepatobiliary Surgery, vol. 13, pp. 385–388, 2007. View at Google Scholar
  126. Y. Q. Shi and T. D. Tian, “Panax notoginseng extract ovrxomes drug resistance of K562/VCR cells,” Chinese Journal of Traditional Medical Science and Technology, vol. 12, pp. 292–294, 2005. View at Google Scholar
  127. L. L. Liu, Y. E. Liu, and G. T. Fang, “Reversal effect of panaxnotoginseng saponins on multidrug resistance breast cancer cell MCF/ADM,” Lishizhen Medicine and Materia Medica Research, vol. 19, pp. 954–956, 2008. View at Google Scholar
  128. X. Q. Peng, W. Feng, and W. H. Zhang, “Reversal of multirug resistance in K562/A02 cell by alcoholic extract of pinellia ternate,” Chinese Journal of Experimental Traditional Medical Formulae, vol. 18, pp. 157–160, 2012. View at Google Scholar
  129. Y. H. Wang, J. Y. Zhao, C. H. Ge, and P. M. Yang, “Reversal effect and mechanism of realgar on multidrug resistance in breast tumor cells MCF-7/ADM,” Progress of Anatomical Sciences, vol. 9, pp. 135–138, 2003. View at Google Scholar
  130. Q. M. Li, B. E. Dan, and J. Zhang, “Reversing effect of thallus laminariae PE on drug resistance in B-MD-C1 (ADR+/+) Cell Line,” Carcinogenesis, Teratogenesis & Mutagenesis, vol. 19, pp. 219–222, 2007. View at Google Scholar
  131. C. M. Yang, X. B. Cui, Q. Luo, L. Sun, H. Liu, and L. X. Zhang, “Curcumin reverses cancer cell drug resistance is mediated by caspase-3,” The Journal of Practical Medicine, vol. 28, pp. 355–357, 2012. View at Google Scholar
  132. Y. X. Chi, Artesunate reversing drug resistance and weakening anti-apoptosis mediated Bcl-2 in gastric cancer cells SGC7901/mdr1 [M.S. thesis], Xinxiang Medical University, Xinxiang, China, 2014.
  133. C. C. Yao, Y. R. Tu, H. X. Du et al., “The effect of elemene on reversal multidurg resistance and the expression of P-glycoprotein in A549/DDP,” Journal of Modern Oncology, vol. 21, pp. 2670–2673, 2013. View at Google Scholar
  134. H. L. Ma, X. J. Zhou, X. Z. Zhang, and T. Wang, “Study of β-elemene on induction of apoptosis and reverses on tamoxifen drug-resist-ance in human breast cancer cells LCC-2,” Journal of Modern Oncology, vol. 22, pp. 2024–2028, 2014. View at Google Scholar
  135. J. Hu, W. Jin, and P.-M. Yang, “Reversal of resistance to adriamycin in human breast cancer cell line MCF-7/ADM by β-elemene,” Chinese Journal of Oncology, vol. 26, no. 5, pp. 268–270, 2004. View at Google Scholar · View at Scopus
  136. X. N. Ouyang, W. Z. Fang, D. S. Wu, S. Q. Lin, J. Chen, and Z. Y. Yu, “The mechanism of rheum emodin reversed resistance of EGFR-TKI in NSCLC,” Chinese Clinical Oncology, vol. 19, pp. 967–971, 2014. View at Google Scholar
  137. F. Zhao, M. H. Zhang, L. Z. Li, C. L. Zhao, and L. Q. Wang, “Research on reversal effect of multidrug resistance in human leukemic cell line by EGCG and its mechanisms,” Journal of Clinical Hematology, vol. 18, pp. 33–36, 2005. View at Google Scholar
  138. S. Hu, Research on the efficiency and mechanisms of gensenoside Rh2 reversing the resistance of lung adenocarcinoma cells to cisplatin [Ph.D. thesis], Zhongnan University, Wuhan, China, 2004.
  139. S. H. Shi and H. Zhang, “Reversal of multidrug resistance by neferine in human gastric carcinoma cell line SGC7901/VCR and its mechanism,” The Practical Journal of Cancer, vol. 27, pp. 334–336, 2012. View at Google Scholar
  140. Y. Liu, K. T. Yao, and G. H. Xiao, “Establishment of the gefitinib-resistant A549/GR cell line of human lung adenocarcinoma and investigation of the mechanism of parthenolide in reversing drug resistance,” Chongqing Medical Journal, vol. 41, pp. 3689–3694, 2012. View at Google Scholar
  141. Q. Ma, F.-X. Zhang, Z.-C. Lv, J.-Y. Chen, and S.-Z. Kang, “Phenylpropanoid glycoside reverse multidrug resistance of colon carcinoma LoVo/Adr cells through induction of apoptosis,” World Chinese Journal of Digestology, vol. 17, no. 23, pp. 2357–2361, 2009. View at Google Scholar · View at Scopus
  142. G. M. Sun, X. H. Li, and B. Z. Wang, “Retinoid acid overcomes drug resistance of MCH7/TAM,” Shandong Medical Journal, vol. 50, pp. 107–108, 2010. View at Google Scholar
  143. Y. Q. Huang, Research on reversal of anti-apoptotic action by tetrandrine on adriamycin-resistant human bladder carcinoma cell line BIU-87/ADM and its possible mechanisms [M.S. thesis], Fujian Medical University, 2011.
  144. J. Hu, J.-Y. Zhao, and P.-M. Yang, “Studies of realgar on induction of apoptosis and reversal of drug resistance in human breast tumor cells MCF-7/ADM,” Acta Anatomica Sinica, vol. 37, no. 6, pp. 665–668, 2006. View at Google Scholar · View at Scopus
  145. Y.-Q. Han, J.-Y. Yuan, Y.-J. Shi, Y. Zhu, and S.-L. Wu, “Reversal effect of berbamine on multidrug resistance of K562/A02 cells and its mechanism,” Journal of Experimental Hematology, vol. 11, no. 6, pp. 604–608, 2003. View at Google Scholar · View at Scopus
  146. X. K. Yu, X. L. Chen, and M. Hou, “Carnosic acid overcomes drug resistance of K562/A02 cells,” Chinese Journal of Practical Internal Medicine, vol. 27, supplement 1, p. 66, 2007. View at Google Scholar
  147. S. Jin, S. E. Chen, M. Zhang et al., “Reversion of MDR of HL60/ADR and MCF-7/ADR with curcumin in vitro,” Chongqing Medical Journal, vol. 39, pp. 21–23, 2010. View at Google Scholar
  148. Y. Y. Chen, J. Li, J. D. Hu et al., “Reversing effects of emodin on multidrug resistance in resistant HL-60/ADR cells,” Journal of Experimental Hematology, vol. 2, pp. 1413–1422, 2013. View at Google Scholar
  149. F. Xue, Z.-Y. Cheng, W.-T. Liang et al., “Resistance reverse effects of honokiol on multidrug resistance of U937/ADR cell line,” Journal of Shanghai Jiaotong University, vol. 29, no. 9, pp. 1035–1039, 2009. View at Google Scholar · View at Scopus
  150. S. Xu, L. Luo, L.-Q. Zhu et al., “Reversal effect of 4′-methylether-scutellarein on multidrug resistance of human choriocarcinoma JAR/VP16 cell line,” Progress in Biochemistry and Biophysics, vol. 33, no. 11, pp. 1061–1073, 2006. View at Google Scholar · View at Scopus
  151. Y. B. Wang, Z. T. Lu, Q. G. Zhang, X. J. Gao, L. G. Zhang, and H. J. Liu, “Effect of quercetin on multidrug resistance reversal of lung adenocarcinoma cell line A549/DDP,” Journal of Binzhou Medical University, vol. 36, pp. 86–89, 2013. View at Google Scholar
  152. Y.-Q. Han, L.-J. Cao, H.-J. Hao, and Y.-J. Shi, “Effects of quercetin on multidrug resistance and expression of related genes in human erythroleukemic K562/a cells,” Journal of Experimental Hematology, vol. 19, no. 4, pp. 884–889, 2011. View at Google Scholar · View at Scopus
  153. Y. Wei, H. Y. Zhang, and G. Liang, “The reverse effect of quercetin on multidrug resistance of human hepatocellular carcinoma,” Tianjing Medical Journal, vol. 40, pp. 1022–1025, 2012. View at Google Scholar
  154. Q. P. Li and Y. N. Gai, “Schisandrin B reverses multidrug resistance due to MDR1-mediated human osteosarcoma cell line U-2 OS/ADR,” Anhui Medical and Pharmaceutical Journal, vol. 18, pp. 1642–1645, 2014. View at Google Scholar
  155. X. Q. Qin, Y. G. Liang, H. Z. Gao et al., “Reversing mechanism of schizandrin A on multi-drug resistance of K562/ADR, HL60/ADR, MCF-7/ADR cell lines,” Chinese Pharmacological Bulletin, vol. 27, pp. 329–333, 2011. View at Google Scholar
  156. J. Cui, J. Ding, Y.-P. Wu, F.-Q. Liu, X.-C. Liu, and Y. Wang, “Reversal effect of sodium selenite on multidrug resistance in K562/ADR cell line and its mechanisms,” Journal of Experimental Hematology, vol. 15, no. 4, pp. 756–761, 2007. View at Google Scholar · View at Scopus
  157. Y. S. Li, J. Y. Liu, and Y. Q. Huang, “Reversing mechanism of multidrug resistance of human bladder carcinoma drug-resistant cell line BIU-87/ADM by tetrandrine,” Chinese Journal of Experimental Surgery, vol. 28, pp. 1526–1529, 2011. View at Google Scholar
  158. X.-D. Gai, C.-Q. Zeng, and M. Hong, “Effect of bupleurun Chinese DC(BCDC) on the MDR reversal of hepatocellular carcinoma and related mechanism,” Chemical Journal of Chinese Universities, vol. 26, no. 8, pp. 1446–1450, 2005. View at Google Scholar · View at Scopus
  159. F. H. Yang, Z. M. Wang, and X. L. Wu, “Grape seed polyphenols reverses multidrug resistance of GBC-SD cell lines,” Chinese Journal of Current Advances in General Surgery, vol. 8, pp. 355–357, 2005. View at Google Scholar
  160. H. F. Shi, H. F. Zhang, Q. Zhao, W. X. Zhao, and J. Dan, “Tea polyphenol overcomes drug resistance of HL60/VCR cells,” Chinese Journal of Gerontology, vol. 31, pp. 258–261, 2011. View at Google Scholar
  161. Y. T. Shi, H. Jing, Y. Wang, J. L. Yi, and C. Y. Liu, “Rat serum containing of Buzhong yiqi decoction reverse chemotherapeutic resistance in A549/DDP cells by down-regulating expression levels of mTOR,” Chinese Journal of Experimental Traditional Medical Formulae, vol. 19, pp. 215–218, 2013. View at Google Scholar
  162. W. K. Ma, Y. M. He, X. M. Yao, Y. Huang, Y. Wang, and Y. J. Li, “Reverse effect of serum containing Jiedu huayu recipe on multidrug resistance of leukemia HL60/Adr cells,” Traditional Chinese Drug Research & Clinical Pharmacology, vol. 22, pp. 524–527, 2011. View at Google Scholar
  163. J. Li and P. P. Liu, “The study about Herba Scutellariae Barbatae reverse the drug resistance of leukemia cell line K562/A02,” Guiding Journal of Traditional Chinese Medicine and Pharmacology, vol. 18, pp. 88–89, 2012. View at Google Scholar
  164. X. L. Zhang, T. Huang, X. F. Yang, L. Huang, and Y. Li, “Experimental studies on reversion effects of shehuang xiaoliu decoction on multidrug resistance of human hepatoma cells,” Chinese Journal of Traditional Medical Science and Technology, vol. 21, pp. 25–27, 2014. View at Google Scholar
  165. S. F. Zhou, J. Chen, and M. Wang, “Reverse effect of zedoary turmeric oil serum on multidrug-resistant of stomach cancer cell line SGC7901/CDDP,” Traditional Chinese Drug Research & Clinical Pharmacology, vol. 23, pp. 508–511, 2012. View at Google Scholar
  166. C. Jiang and X. G. Yang, “Study on ligustrazine combined with chemotherapy in patients with relapsed or refractory non-Hodgkin's lymphoma,” Journal of International Oncology, vol. 37, pp. 397–400, 2010. View at Google Scholar
  167. X. C. Wang, “Multidrug resistance reversal effect of breast cancer by wuweizi dranule combined with CAF chemotherapy,” Chinese Journal of Experimental Traditional Medical Formulae, vol. 20, pp. 241–243, 2014. View at Google Scholar
  168. J. H. Xu, Z. Z. Fan, J. Sun et al., “Effects of ‘Chang Wei Qing’ in treating advanced gastrointestinal cancer and its effects on peripheral blood MDR1 mRNA,” Shanghai Journal of Traditional Chinese Medicine, vol. 41, pp. 40–42, 2007. View at Google Scholar
  169. H. L. Chen, X. L. Yang, and P. J. Yang, “Treatment of gastric cancer with Didang formula,” China Health Industry, vol. 8, pp. 59–60, 2011. View at Google Scholar
  170. Y. X. Zhang, C. H. Li, W. G. Song, and L. Jiang, “Treatment of liver cancer using Xiaochaihu formula,” Seek Medical and Ask the Medicine, vol. 11, pp. 486–487, 2013. View at Google Scholar
  171. P. Shu and S. L. Liu, “Clinical observation on reversal effects of multi-drug resistance gene and lung resistance protein in gastric cancer treated by shenqi jiangwei decoction,” Hunan Journal of Traditional Chinese Medicine, vol. 24, pp. 1–2, 2008. View at Google Scholar
  172. C. Y. Huang, J. Q. Chen, Y. Shen, H. H. Xie, and X. Y. Nie, “Study on the effect of Pingxiao capsule on multidrug resistant gene P-gp, TOPOII and GST-π for breast cancer,” Lingnan Modern Clinics in Surgery, vol. 11, pp. 38–40, 2011. View at Google Scholar
  173. Q. J. Chen, R. Zhang, H. L. Situ et al., “Effects of Fukangling capsule on multidrug resistant geneprotein p170 and GST-π of breast cancer,” China Pharmacy, vol. 19, pp. 1650–1651, 2008. View at Google Scholar
  174. S. C. Zhang, X. Q. Zhang, F. W. Zhou, L. F. Yang, and X. J. Zhao, “Study of Qiankun capsule on mechanism of raising efficiency and reducing toxicity during chemotherapy in non-small cell lung cancer,” Hebei Journal of Traditional Chinese Medicine, vol. 32, pp. 1448–1450, 2010. View at Google Scholar